# IDYA — Ideaya Biosciences Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IDYA  
**Sources:** 19  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-idya-ideaya-biosciences-inc-catalysts-narrative-risks-10388

---

# IDEAYA Biosciences Inc. (NASDAQ: IDYA) — Publicly Traced Asset Review

*As of the Oct 30, 2026 close, IDYA traded at ~$31.96 with a market cap of ~$3.1B [[11]](https://www.marketbeat.com/earnings/reports/2026-11-9-ideaya-biosciences-inc-stock/), [[12]](https://askthedate.com/America/New_York/en/earnings-calendar/2026-11-10/IDYA/). IDEAYA is a San Francisco-based, pre-commercial precision medicine oncology company targeting molecularly defined cancers, led by darovasertib (PKC inhibitor in uveal melanoma), plus DLL3 (IDE849) and MTAP-deleted (IDE397/IDE892) programs [[11]](https://www.marketbeat.com/earnings/reports/2026-11-9-ideaya-biosciences-inc-stock/), [[18]](https://ir.ideayabio.com/), [[20]](https://www.ideayabio.com/).*

## Recent Catalysts (roughly July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-idya-ideaya-biosciences-inc-catalysts-narrative-risks-10388 (free to sign up)._